{
    "elements": [
        {
            "type": "image",
            "sequence_num": 1,
            "data": {
                "url": "12007 VTE DVT  PE during antenatal & postnatal period 3.1.001.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 2,
            "data": {
                "num_rows": 15,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Title:"
                    },
                    {
                        "text": "MANAGEMENT OF WOMEN WITH VENOUS THROMBOEMBOLISM (VTE), DEEP VEIN THROMBOSIS (DVT) OR PULMONARY EMBOLISM (PE) DURING ANTENATAL AND POSTNATAL PERIOD"
                    },
                    {
                        "text": "Document Reference/Register no:"
                    },
                    {
                        "text": "12007"
                    },
                    {
                        "text": "Version Number:"
                    },
                    {
                        "text": "3.1"
                    },
                    {
                        "text": "Document type: (Policy/ Guideline/ SOP)"
                    },
                    {
                        "text": "Guideline"
                    },
                    {
                        "text": "To be followed by: (Target Staff)"
                    },
                    {
                        "text": "Midwives, Obstetricians, Anaesthetists, Paediatricians"
                    },
                    {
                        "text": "Ratification Issue Date: (Date document is uploaded onto the intranet)"
                    },
                    {
                        "text": "22 August 2019"
                    },
                    {
                        "text": "Review Date:"
                    },
                    {
                        "text": "21 August 2022"
                    },
                    {
                        "text": "Developed in response to:"
                    },
                    {
                        "text": "Intrapartum NICE Guidelines RCOG Guideline 2015"
                    },
                    {
                        "text": "Contributes to HSC Act 2008 (Regulated Activities) Regulations 2014(Part 3); and CQC Regulations 2009 (Part 4) CQC Fundamental Standards of Quality and Safety:"
                    },
                    {
                        "text": "12"
                    },
                    {
                        "text": "Issuing Division/Directorate:"
                    },
                    {
                        "text": "Women's and Children's"
                    },
                    {
                        "text": "Author/Contact: (Asset Administrator)"
                    },
                    {
                        "text": "Anita Dutta, Consultant Obstetrician"
                    },
                    {
                        "text": "Hospital Sites: (tick appropriate box/es to indicate status of policy review i.e. joint/ independent)"
                    },
                    {
                        "text": "\u2610 MSE NHS Foundation Trust \u2610 Basildon Hospital \u2612 Broomfield Hospital \u2610 Southend Hospital \u2610 Other (please state)"
                    },
                    {
                        "text": "Consultation:"
                    },
                    {
                        "text": "(Refer to page 2)"
                    },
                    {
                        "text": "Approval Group / Committee(s):"
                    },
                    {
                        "text": "n/a"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "n/a"
                    },
                    {
                        "text": "Professionally Approved by: (Asset Owner)"
                    },
                    {
                        "text": "Miss Rao, Lead Consultant for Obstetrics and Gynaecology"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "21 June 2019"
                    },
                    {
                        "text": "Ratification Group(s):"
                    },
                    {
                        "text": "Document Ratification Group"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "26 June 2019"
                    },
                    {
                        "text": "Executive and Clinical Directors (Communication of minutes from Document Ratification Group"
                    },
                    {
                        "text": "Date: August 2019"
                    },
                    {
                        "text": "Distribution Method:"
                    },
                    {
                        "text": "Trust Intranet/ Internet"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "image",
            "sequence_num": 3,
            "data": {
                "url": "12007 VTE DVT  PE during antenatal & postnatal period 3.1.002.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 4,
            "data": {
                "num_rows": 12,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Consulted With:"
                    },
                    {
                        "text": "Post/ Approval Committee/ Group:"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "Anita Rao/ Alison Cuthbertson"
                    },
                    {
                        "text": "Clinical Director for Women's and Children's Directorate"
                    },
                    {
                        "text": "21 June 2019"
                    },
                    {
                        "text": "Alison Cuthbertson"
                    },
                    {
                        "text": "Head of Midwifery / Nursing"
                    },
                    {
                        "text": "Madhu Joshi"
                    },
                    {
                        "text": "Consultant for Obstetrics and Gynaecology"
                    },
                    {
                        "text": "Angela Woolfenden"
                    },
                    {
                        "text": "Acting Lead Midwife Community"
                    },
                    {
                        "text": "Amanda Dixon"
                    },
                    {
                        "text": "Lead Midwife Acute Inpatient Services"
                    },
                    {
                        "text": "Chris Berner"
                    },
                    {
                        "text": "Lead Midwife Clinical Governance"
                    },
                    {
                        "text": "Alison Groves"
                    },
                    {
                        "text": "Senior Midwife Co -Located Birthing Unit"
                    },
                    {
                        "text": "Tegan Winnington"
                    },
                    {
                        "text": "Senior Midwife WJC, Braintree"
                    },
                    {
                        "text": "Rosie Newman"
                    },
                    {
                        "text": "Senior Midwife St Peters, Maldon"
                    },
                    {
                        "text": "Claire Fitzgerald"
                    },
                    {
                        "text": "Pharmacy"
                    },
                    {
                        "text": "Ruth Byford"
                    },
                    {
                        "text": "Warner Library"
                    },
                    {
                        "text": "27 June 2019"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 5,
            "data": {
                "num_rows": 1,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Related Trust Policies (to be read in conjunction with)"
                    },
                    {
                        "text": "04071 Policy for standard infection prevention precautions 04072 Hand hygiene policy 06036 Maternity record keeping including documentation in handheld records 08033 Thromboprophylaxis and treatment during labour and delivery including Caesarean section 08014 Venousthromboembolism (VTE) risk assessment and Thromboprophylaxis in Maternity 09095 The severely ill patient in Maternity Services 08079 Clinical audit strategy and policy"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 6,
            "data": {
                "num_rows": 6,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Review History:"
                    },
                    {
                        "text": "Version No:"
                    },
                    {
                        "text": "Authored/Reviewer:"
                    },
                    {
                        "text": "Summary of amendments/ Record documents superseded by:"
                    },
                    {
                        "text": "Issue Date:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Dr T T Wai"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "24 January 2013"
                    },
                    {
                        "text": "2.0"
                    },
                    {
                        "text": "Dr Richard Haines"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "April 2016"
                    },
                    {
                        "text": "3.0"
                    },
                    {
                        "text": "Anita Dutta"
                    },
                    {
                        "text": "Full review"
                    },
                    {
                        "text": "22 August 2019"
                    },
                    {
                        "text": "3.1"
                    },
                    {
                        "text": "Rachel Smith"
                    },
                    {
                        "text": "Amendment to Appendix F for VTE Risk assessment change to \u201cage 35 years and older\u201d following action plan from SI"
                    },
                    {
                        "text": "02 March 2021"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 7,
            "data": {
                "is_heading": 1,
                "text": "INDEX"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 8,
            "data": {
                "is_heading": 1,
                "prefix": 1.0,
                "text": "Purpose"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 9,
            "data": {
                "is_heading": 0,
                "prefix": 1.1,
                "text": "This guideline is designed to help Trust staff regarding the immediate investigation and management of women in whom venous thromboembolism (VTE) is suspected during pregnancy or the puerperium."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 10,
            "data": {
                "is_heading": 0,
                "text": "(Refer to the guideline entitled \u2018Thromboprophylaxis and treatment during labour and delivery including caesarean section'; register number 08033 and \u2018VTE risk assessment and thromboprophylaxis in Maternity'; register number 08014)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 11,
            "data": {
                "is_heading": 1,
                "prefix": 2.0,
                "text": "Equality Impact Assessment"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 12,
            "data": {
                "is_heading": 0,
                "prefix": 2.1,
                "text": "Mid Essex Hospital Services NHS Trust is committed to the provision of a service that is fair, accessible and meets the needs of all individuals."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 13,
            "data": {
                "is_heading": 0,
                "text": "(Refer to Appendix G)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 14,
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Background"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 15,
            "data": {
                "is_heading": 0,
                "prefix": 3.1,
                "text": "Venous thromboembolism remains the main direct cause of maternal death in the UK and sequential reports of Confidential Enquiries into Maternal Deaths have highlighted failures in obtaining objective diagnoses and employing adequate treatment."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 16,
            "data": {
                "is_heading": 0,
                "prefix": 3.2,
                "text": "If VTE is untreated, 15\u201324% of patients with venous thrombosis will develop pulmonary embolism. During pregnancy this is fatal in almost 15% of women, 66% of whom will die within 30 minutes of the embolic event."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 17,
            "data": {
                "is_heading": 0,
                "prefix": 3.3,
                "text": "The subjective, clinical assessment of deep venous thrombosis (DVT) and pulmonary thromboembolism (PTE) is particularly unreliable in pregnancy. Many of the classical symptoms of VTE, including tachycardia, tachypnoea, dyspnoea and leg swelling, can also be associated with normal pregnancy."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 18,
            "data": {
                "is_heading": 0,
                "prefix": 3.4,
                "text": "A minority of women with clinically suspected VTE have the diagnosis confirmed when objective testing is employed (only around 5% of investigations will have a positive result)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 19,
            "data": {
                "is_heading": 0,
                "prefix": 3.5,
                "text": "However, VTE is up to ten times more common in pregnant women than in non-pregnant women of the same age and can occur at any stage of pregnancy but the puerperium is the time of highest risk."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 20,
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "Recommendations"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 21,
            "data": {
                "is_heading": 0,
                "prefix": 4.1,
                "text": "Any woman with signs and symptoms suggestive of VTE should have objective testing performed expeditiously. (Refer to points 5.0 and 6.0)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 22,
            "data": {
                "is_heading": 0,
                "prefix": 4.2,
                "text": "Then, treatment with low-molecular-weight heparin (LMWH) (section 9 and Appendix A) until the diagnosis is excluded by objective testing, unless treatment is strongly contraindicated."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 23,
            "data": {
                "is_heading": 0,
                "prefix": 4.3,
                "text": "All pregnant women should be treated with clexane, unless contraindicated, and referred to the hospital anticoagulant clinic for monitoring of anticoagulant treatment."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 24,
            "data": {
                "is_heading": 0,
                "prefix": 4.4,
                "text": "In massive pulmonary embolism with cardiovascular compromise, immediate unfractionated heparin is the preferred treatment."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 25,
            "data": {
                "is_heading": 0,
                "text": "(Refer to Appendix B)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 26,
            "data": {
                "is_heading": 0,
                "prefix": 4.5,
                "text": "Elective induction of labour may be indicated in these women to help plan for antithrombotic management around delivery."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 27,
            "data": {
                "is_heading": 0,
                "prefix": 24.0,
                "text": "For example, if the woman takes the morning dose but omits the evening dose on the day before induction of labour, she could have an early elective epidural sited the next day (when it will be  hours since her last dose of LMWH)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 28,
            "data": {
                "is_heading": 0,
                "prefix": 4.7,
                "text": "If LMWH precludes regional techniques (in, for example, the woman who presents in spontaneous labour within 12 hours of taking a LMWH dose) alternative analgesia such as opiate-based intravenous patient controlled analgesia can be offered."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 29,
            "data": {
                "is_heading": 0,
                "prefix": 4.8,
                "text": "Generally, therapeutic anticoagulant therapy should be continued for at least 6 weeks postnatally and until at least 3 months of treatment has been given in total."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 30,
            "data": {
                "is_heading": 0,
                "prefix": 4.9,
                "text": "Women should be advised that neither heparin (unfractionated or LMWH) nor warfarin is contraindicated in breastfeeding."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 31,
            "data": {
                "is_heading": 0,
                "prefix": 4.1,
                "text": "D-dimer testing should not be performed to diagnose acute VTE in pregnancy. D-dimer can be elevated because of the physiological changes in the coagulation system and levels become \u2018abnormal' at term and in the postnatal period in most healthy pregnant women."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 32,
            "data": {
                "is_heading": 0,
                "prefix": 4.11,
                "text": "The anticoagulant treatment of PE follows the same principles of treatment of deep vein thrombosis (DVT), with clexane and warfarin."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 33,
            "data": {
                "is_heading": 0,
                "prefix": 4.12,
                "text": "Patients who develop a VTE during pregnancy or the postnatal period should be offered postnatal appointment with a haematologist."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 34,
            "data": {
                "is_heading": 0,
                "prefix": 4.13,
                "text": "Full thrombophilia tests should be performed after anticoagulants are stopped; preferably in haematology clinics."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 35,
            "data": {
                "is_heading": 1,
                "prefix": 5.0,
                "text": "Diagnosis of Acute DVT"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 36,
            "data": {
                "is_heading": 0,
                "prefix": 5.1,
                "text": "Acute DVT should be suspected if presented with leg pain and swelling (usually unilateral), lower abdominal pain, low-grade pyrexia, particularly if there are other risk factors for VTE."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 37,
            "data": {
                "is_heading": 0,
                "prefix": 5.2,
                "text": "Wells scoring system is not usually applicable in pregnancy as some scoring points e.g. pitting oedema and leg swelling, can also be associated with normal pregnancy. But it may help in assessing the risk in general."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 38,
            "data": {
                "is_heading": 1,
                "text": "Wells DVT clinical probability assessment"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 39,
            "data": {
                "is_heading": 1,
                "prefix": -2.0,
                "text": "Clinical Feature Score Active cancer (treatment on-going or within previous 6 months or palliative) 1 Paralysis, plaster 1 Bed > 3 days, surgery within 4 weeks 1 Tenderness along veins Entire leg swollen Calf swollen > 3cm 1 Pitting Oedema 1 Collateral veins 1 Alternative diagnosis likely  Low: 0 or less; moderate: 1 or 2; high: 3 or more."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 40,
            "data": {
                "is_heading": 0,
                "prefix": 5.3,
                "text": "Compression duplex ultrasound should be undertaken on the same day."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 41,
            "data": {
                "is_heading": 0,
                "prefix": 5.4,
                "text": "If a same day scan is not available then a therapeutic dose of clexane should be given daily until a reported scan is available."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 42,
            "data": {
                "is_heading": 0,
                "prefix": 7.0,
                "text": "If ultrasound is negative and there is a low level of suspicion, anticoagulant treatment can be discontinued. If ultrasound is negative and a high level of suspicion exists, anticoagulant treatment should be discontinued BUT the ultrasound should be repeated on days 3 and"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 43,
            "data": {
                "is_heading": 0,
                "prefix": 5.6,
                "text": "If repeat testing is negative, anticoagulant treatment should be discontinued."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 44,
            "data": {
                "is_heading": 0,
                "prefix": 5.7,
                "text": "When iliac vein thrombosis is suspected (back pain and swelling of the entire limb), magnetic resonance venography or conventional contrast venography may be considered, to discuss further radiological investigation with consultant radiologist."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 45,
            "data": {
                "is_heading": 1,
                "prefix": 6.0,
                "text": "Diagnosis of an Acute Pulmonary Embolism"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 46,
            "data": {
                "is_heading": 0,
                "prefix": 6.1,
                "text": "Breathlessness is experienced by up to 75% of pregnant women due to physiological changes. It can start in any trimester, and the onset is gradual. It is often noticed by the woman when she is talking or at rest, although it may get worse with exercise."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 47,
            "data": {
                "is_heading": 0,
                "prefix": 6.2,
                "text": "Chest symptoms are often vague and non-specific, but when new symptoms are reported in pregnancy or the puerperium there should be a low threshold for investigation, particularly when other risk factors such as obesity are present."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 48,
            "data": {
                "is_heading": 0,
                "prefix": 6.3,
                "text": "Diagnosis of pulmonary embolus is considered if sudden onset of breathlessness may have associated pleuritic pain, haemoptysis, dizziness."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 49,
            "data": {
                "is_heading": 0,
                "prefix": 6.4,
                "text": "Clinicians should be aware that at present there is no evidence to support the use of pretest probability assessment in the management of acute VTE in pregnancy. Wells scoring system may help as additional risk factors to consider the diagnosis of pulmonary embolism, but scoring system is used for male patients and non pregnant female patients."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 50,
            "data": {
                "is_heading": 1,
                "text": "Wells PE Clinical Probability Score"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 51,
            "data": {
                "is_heading": 0,
                "text": "Clinical Feature  Patient Score"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 52,
            "data": {
                "is_heading": 0,
                "prefix": 3.0,
                "text": "Clinical sign DVT  3 Heart Rate >100/min  1.5 Immobilisation \u2265 3 days or surgery previous 4 weeks   1.5 Previous DVT or PE  1.5 Haemoptysis  1 Malignancy unless in remission >6 months  3 PE as likely or more likely than alternative diagnosis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 53,
            "data": {
                "is_heading": 0,
                "text": "Score of 4 or less = PE unlikely; Score greater than >4 = PE likely"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 54,
            "data": {
                "is_heading": 0,
                "prefix": 6.5,
                "text": "Check maternal vital sign; tachycardia and techypnoea; Measurement of oxygen saturations at rest and on exercise (in normal women, the oxygen saturation ranges from 96 to 100% and does not fall below 95% on exercise)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 55,
            "data": {
                "is_heading": 0,
                "prefix": 6.6,
                "text": "If high clinical probability of PE, perform arterial blood gas to assess hypoxia and respiratory acidosis."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 56,
            "data": {
                "is_heading": 0,
                "prefix": 6.7,
                "text": "Full blood count and renal function \u2013 before CTPA and starting anticoagulation."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 57,
            "data": {
                "is_heading": 0,
                "prefix": 6.8,
                "text": "Chest X-ray, ECG. Where there is clinical suspicion of acute PE, ECG and a chest X-ray should be performed. Abnormal features of chest X-ray caused by PTE include atelectasis, effusion, focal opacities, regional oligaemia or pulmonary oedema."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 58,
            "data": {
                "is_heading": 0,
                "prefix": 6.9,
                "text": "If a persistent clinical suspicion of acute PTE, an urgent perfusion (V/Q) lung scan or a computed tomography pulmonary angiogram (CTPA) should be performed on the same day."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 59,
            "data": {
                "is_heading": 0,
                "prefix": 6.1,
                "text": "When chest X-ray is abnormal and there is clinical suspicion of PE, CTPA should be performed in preference to a V/Q scan."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 60,
            "data": {
                "is_heading": 0,
                "prefix": 6.11,
                "text": "Where feasible, women should be involved in the decision to undergo CTPA or perfusion (V/Q) scanning. Ideally, informed consent should be obtained before these tests are undertaken (consent for VQ and CTPA). (Refer to Appendix D)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 61,
            "data": {
                "is_heading": 0,
                "prefix": 6.12,
                "text": "If a scan is not undertaken on the day of suspected diagnosis then therapeutic doses of clexane should be given until a reported scan is available. (Refer to Appendix A)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 62,
            "data": {
                "is_heading": 0,
                "prefix": 6.13,
                "text": "If V/Q scan or CTPA and duplex Doppler are normal but the clinical suspicion of PTE is high, repeat or alternative testing should be carried out. Anticoagulant treatment should be continued until PTE is definitively excluded."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 63,
            "data": {
                "is_heading": 0,
                "prefix": 6.14,
                "text": "D-dimer testing should not be performed."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 64,
            "data": {
                "is_heading": 1,
                "prefix": 7.0,
                "text": "Management of Massive Life-threatening PTE in Pregnancy"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 65,
            "data": {
                "is_heading": 0,
                "prefix": 7.1,
                "text": "Observations of vital signs should be commence and recorded on the MEOWS chart. (Refer to the guideline entitled \u2018The severely ill patient in Maternity Services'; register number 09095)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 66,
            "data": {
                "is_heading": 0,
                "prefix": 7.2,
                "text": "Collapsed and shocked patients need to be assessed by the obstetric registrar /on call consultant and anaesthetist on call."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 67,
            "data": {
                "is_heading": 0,
                "prefix": 7.3,
                "text": "The on call consultant obstetrician and anaesthetic consultant should be informed immediately. Following initial assessment, an individual management plan should be documented in the patient's health care records by the obstetric and anaesthetic consultants."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 68,
            "data": {
                "is_heading": 0,
                "text": "(Refer to the guideline for the \u2018Severely ill pregnant patient'; register number 09095)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 69,
            "data": {
                "is_heading": 0,
                "prefix": 7.4,
                "text": "The medical team should be called urgently; any subsequent assessments should be documented in the patient's health care records."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 70,
            "data": {
                "is_heading": 0,
                "prefix": 7.5,
                "text": "An urgent portable echocardiogram or computer tomography of pulmonary artery (CTPA) within 1 hour of presentation should be arranged."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 71,
            "data": {
                "is_heading": 0,
                "prefix": 7.6,
                "text": "If the diagnosis is confirmed, immediate thrombolysis is needed."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 72,
            "data": {
                "is_heading": 0,
                "prefix": 7.7,
                "text": "Intravenous unfractionated heparin is the preferred treatment in massive PTE with cardio-vascular compromise."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 73,
            "data": {
                "is_heading": 0,
                "text": "(Refer to Appendix B)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 74,
            "data": {
                "is_heading": 0,
                "prefix": 7.8,
                "text": "The haematologist, radiologist and ITU consultant should be contacted as clinically indicated."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 75,
            "data": {
                "is_heading": 1,
                "prefix": 8.0,
                "text": "Cerebral Thrombosis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 76,
            "data": {
                "is_heading": 0,
                "prefix": 8.1,
                "text": "Persisted vomiting in the third trimester is not normal and should be investigated thoroughly."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 77,
            "data": {
                "is_heading": 0,
                "prefix": 8.2,
                "text": "Women presented with headache, dizziness and neurological symptoms are important and to ensure review by senior doctor; if necessary, refer to medical team."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 78,
            "data": {
                "is_heading": 0,
                "prefix": 8.3,
                "text": "They may have medical complications and a co-existent encephalopathy developed vomiting that could have caused dehydration. It can predisposed to VTE."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 79,
            "data": {
                "is_heading": 0,
                "prefix": 8.4,
                "text": "Women with protracted vomiting should be given thiamine because of the recognised risk of Wernicke's encephalopathy."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 80,
            "data": {
                "is_heading": 1,
                "prefix": 9.0,
                "text": "Antenatal Management of VTE"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 81,
            "data": {
                "is_heading": 0,
                "prefix": 9.1,
                "text": "The obstetric registrar/consultant should document an individual management plan in collaboration with the medical and anaesthetic teams, in the patient's health care records for patients who require thromboprophylaxis or treatment for a diagnosis of VTE."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 82,
            "data": {
                "is_heading": 0,
                "prefix": 9.2,
                "text": "All pregnant women should be treated with clexane, unless contraindicated, and referred to the hospital anticoagulant clinic for monitoring of anticoagulant treatment."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 83,
            "data": {
                "is_heading": 0,
                "text": "(Refer to Appendix A)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 84,
            "data": {
                "is_heading": 0,
                "prefix": 9.3,
                "text": "Treatment with therapeutic doses of subcutaneous clexane should be employed during the remainder of the pregnancy."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 85,
            "data": {
                "is_heading": 0,
                "prefix": 9.4,
                "text": "Oral anticoagulants"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 86,
            "data": {
                "is_heading": 0,
                "text": "Because of their adverse effects on the fetus, oral anticoagulants should not be used for antenatal VTE treatment;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 87,
            "data": {
                "is_heading": 0,
                "text": "Oral anticoagulants cross the placenta readily and are associated with a characteristic embryopathy in the first trimester, central nervous system abnormalities which occur during any trimester, fetal haemorrhage and neonatal haemorrhage following the trauma of delivery."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 88,
            "data": {
                "is_heading": 1,
                "prefix": 10.0,
                "text": "Management for Women at High Risk of Haemorrhage"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 89,
            "data": {
                "is_heading": 0,
                "prefix": 10.1,
                "text": "Any woman who is considered to be at high-risk of haemorrhage and in whom continued heparin treatment is considered essential should be managed with intravenous, unfractionated heparin until the risk factors for haemorrhage have resolved."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 90,
            "data": {
                "is_heading": 0,
                "prefix": 10.2,
                "text": "Risk factors include major antepartum haemorrhage, coagulopathy, progressive wound haematoma, suspected intra-abdominal bleeding and postpartum haemorrhage."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 91,
            "data": {
                "is_heading": 0,
                "prefix": 10.3,
                "text": "Unfractionated heparin has a shorter half-life than LMWH and its activity is more completely reversed with protamine sulphate."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 92,
            "data": {
                "is_heading": 0,
                "prefix": 10.4,
                "text": "If a woman develops a haemorrhagic problem while on LMWH, the treatment should be stopped and expert haematological advice sought."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 93,
            "data": {
                "is_heading": 1,
                "prefix": 11.0,
                "text": "Postnatal Management of VTE"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 94,
            "data": {
                "is_heading": 0,
                "prefix": 11.1,
                "text": "Patients who develop a VTE during pregnancy or the postnatal period should be offered a postnatal appointment with a haematologist."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 95,
            "data": {
                "is_heading": 0,
                "prefix": 11.2,
                "text": "Generally, therapeutic anticoagulant therapy should be continued for at least 6 weeks postnatally and until at least 3 months of treatment has been given in total."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 96,
            "data": {
                "is_heading": 0,
                "prefix": 11.3,
                "text": "National guidelines in the UK recommend that, in non-pregnant patients, anticoagulant therapy should be continued for 6 weeks for calf vein thrombosis and 3 months for proximal DVT or pulmonary embolism when VTE has occurred in relation to a temporary risk factor and 6 months for a first episode of idiopathic VTE."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 97,
            "data": {
                "is_heading": 0,
                "prefix": 11.4,
                "text": "Women should be advised that neither heparin (unfractionated or LMWH) nor warfarin is contraindicated in breastfeeding."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 98,
            "data": {
                "is_heading": 0,
                "prefix": 11.5,
                "text": "If the woman chooses to continue with LMWH postnatally, then either the doses that were employed antenatally can be continued or the manufacturers' recommended doses for the non-pregnant patient can be employed (enoxaparin 1.5mg/kg once daily, dalteparin 10,000\u201318,000 units once daily depending on body weight, tinzaparin 175 units/kg once daily)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 99,
            "data": {
                "is_heading": 0,
                "prefix": 14.0,
                "text": "Obstetric patients who are postoperative and receiving unfractionated heparin should have platelet count monitoring performed every 2-3 days from days 4 to  or until heparin is stopped."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 100,
            "data": {
                "is_heading": 1,
                "prefix": 11.7,
                "text": "Postpartum Warfarin (Refer to Appendix C)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 101,
            "data": {
                "is_heading": 0,
                "text": "Warfarin should be avoided until at least the fifth day and for longer in women at increased risk of postpartum haemorrhage;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 102,
            "data": {
                "is_heading": 0,
                "text": "Daily testing of the international normalised ratio (INR) is recommended during the transfer from LMWH to warfarin to avoid over anticoagulation;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 103,
            "data": {
                "is_heading": 0,
                "text": "The INR should be checked on day 2 of warfarin treatment and subsequent warfarin doses titrated to maintain the INR between 2 to 3;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 104,
            "data": {
                "is_heading": 0,
                "text": "Heparin treatment should be continued until the INR is greater than 2 on two successive days;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 105,
            "data": {
                "is_heading": 0,
                "text": "There is an established nurse-led, outpatient DVT service (particularly for monitoring of warfarin treatment) based on the emergency assessment unit. Selected outpatients from within the hospital may also be accepted; contact the emergency assessment unit to discuss individual cases."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 106,
            "data": {
                "is_heading": 0,
                "prefix": 11.8,
                "text": "Full thrombophilia tests should be performed after anticoagulants are stopped; preferably in haematology clinics."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 107,
            "data": {
                "is_heading": 0,
                "prefix": 12.0,
                "text": "Women should be advised that prolonged use of LNWH (more than  weeks) is associated with a significantly lower chance of developing post-thrombotic syndrome."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 108,
            "data": {
                "is_heading": 1,
                "prefix": 12.0,
                "text": "Staff and Training"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 109,
            "data": {
                "is_heading": 0,
                "prefix": 12.1,
                "text": "All qualified midwifery and obstetric staff are fully trained to perform an initial assessment antenatally and to inform the appropriate multidisciplinary members as necessary. Qualified staff should assist midwifery and medical trainee's to learn how to assess and identify women who may require thrombophrophylaxis as part of their education and skills where appropriate to ensure safe competent practitioner."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 110,
            "data": {
                "is_heading": 0,
                "prefix": 12.2,
                "text": "All midwifery and obstetric staff must attend yearly mandatory training which includes skills and drills training."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 111,
            "data": {
                "is_heading": 0,
                "prefix": 12.3,
                "text": "All midwifery and obstetric staff are to ensure that their knowledge and skills are up-to date in order to complete their portfolio for appraisal."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 112,
            "data": {
                "is_heading": 1,
                "prefix": 13.0,
                "text": "Professional Midwifery Advocates"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 113,
            "data": {
                "is_heading": 0,
                "prefix": 13.1,
                "text": "Professional Midwifery Advocates provide a mechanism of support and guidance to women and midwives. Professional Midwifery Advocates are experienced practising midwives who have undertaken further education in order to supervise midwifery services and to advise and support midwives and women in their care choices."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 114,
            "data": {
                "is_heading": 1,
                "prefix": 14.0,
                "text": "Infection Prevention"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 115,
            "data": {
                "is_heading": 0,
                "prefix": 14.1,
                "text": "All staff should follow Trust guidelines on infection prevention by ensuring that they effectively \u2018decontaminate their hands' before and after each procedure and when taking bloods samples to use the Aseptic Non \u2013Touch Technique (ANTT)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 116,
            "data": {
                "is_heading": 0,
                "text": "(Hand hygiene; register number 04072)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 117,
            "data": {
                "is_heading": 1,
                "prefix": 15.0,
                "text": "Audit and Monitoring"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 118,
            "data": {
                "is_heading": 0,
                "prefix": 15.1,
                "text": "Topics for formal audit are selected on an annual basis in accordance with the requirements the Clinical Audit Strategy and Policy (register number 08076), the Corporate Clinical Audit and Quality Improvement Project Plan and the Maternity Annual Audit Work Plan."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 119,
            "data": {
                "is_heading": 0,
                "prefix": 15.2,
                "text": "Audit of compliance with this guideline will be considered based on national and local audit findings and clinical governance data identifying themes suggesting care delivery is suboptimal. If audit of this guideline is identified as a priority, the Women's and Children's Clinical Audit Group will identify a lead for the audit."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 120,
            "data": {
                "is_heading": 0,
                "prefix": 15.3,
                "text": "The findings of the audit will be reported to and approved by the Women's and Children's Clinical Audit Group and an action plan with named leads and timescales will be developed to address any identified deficiencies. Performance against the action plan will be monitored by this group at subsequent meetings."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 121,
            "data": {
                "is_heading": 0,
                "prefix": 15.4,
                "text": "Any significant concerns relating to compliance with the requirements of this guideline will be entered on the local Risk Assurance Framework."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 122,
            "data": {
                "is_heading": 0,
                "prefix": 15.5,
                "text": "Key findings and learning points from the audit will be submitted to the Clinical Governance Group within the quarterly Women's and Children's Directorate Governance report."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 123,
            "data": {
                "is_heading": 0,
                "prefix": 15.6,
                "text": "Key findings and learning points will be disseminated to relevant staff."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 124,
            "data": {
                "is_heading": 1,
                "prefix": 16.0,
                "text": "Guideline Management"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 125,
            "data": {
                "is_heading": 0,
                "prefix": 16.1,
                "text": "As an integral part of the knowledge, skills framework, staff are appraised annually to ensure competency in computer skills and the ability to access the current approved guidelines via the Trust's intranet site."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 126,
            "data": {
                "is_heading": 0,
                "prefix": 16.2,
                "text": "Quarterly memos are sent to line managers to disseminate to their staff the most currently approved guidelines available via the intranet and clinical guideline folders, located in each designated clinical area."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 127,
            "data": {
                "is_heading": 1,
                "prefix": 17.0,
                "text": "Communication"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 128,
            "data": {
                "is_heading": 0,
                "prefix": 17.1,
                "text": "A quarterly \u2018maternity newsletter' is issued and available to all staff including an update on the latest \u2018guidelines' information such as a list of newly approved guidelines for staff to acknowledge and familiarise themselves with and practice accordingly."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 129,
            "data": {
                "is_heading": 0,
                "prefix": 17.2,
                "text": "Approved guidelines are published monthly in the Trust's Focus Magazine that is sent via email to all staff."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 130,
            "data": {
                "is_heading": 1,
                "prefix": 18.0,
                "text": "References"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 131,
            "data": {
                "is_heading": 0,
                "text": "National Institute for Health and Care Excellence, (2012). Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. Clinical guideline 144.Available at: https://www.nice.org.uk/guidance/cg144"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 132,
            "data": {
                "is_heading": 0,
                "text": "Royal College of Obstetricians and Gynaecologists, (2015) Thrombosis and embolism during pregnancy and the puerperium: acute management. Green-top Guideline No. 37b. Available at: https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg37b/"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 133,
            "data": {
                "is_heading": 0,
                "text": "Prevention and Treatment of Venous Thrombo-Embolism (VTE): Risk Assessment and Prophylaxis; MEHT Clinical Guideline; Register No: 09051"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 134,
            "data": {
                "is_heading": 0,
                "text": "S Matthews, 2006. Short communication: imaging pulmonary embolism in pregnancy: what is the most appropriate imaging protocol? The British Journal of Radiology, 79 (941), pp441\u2013444"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 135,
            "data": {
                "is_heading": 1,
                "text": "Appendix A LMWH \u2013 Therapeutic Treatment"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 136,
            "data": {
                "is_heading": 0,
                "text": "It is preferable, safe and effective to treat pregnant women with clexane rather than warfarin."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 137,
            "data": {
                "is_heading": 0,
                "text": "All pregnant women should be treated with clexane, unless contraindicated, and referred to the"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 138,
            "data": {
                "is_heading": 0,
                "text": "hospital anticoagulant clinic for monitoring of anticoagulant treatment."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 139,
            "data": {
                "is_heading": 0,
                "text": "As baseline blood investigations, before anticoagulant therapy is commenced, blood should be taken for a full blood count, coagulation screen, urea and electrolytes and liver function tests."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 140,
            "data": {
                "is_heading": 0,
                "text": "LMWH should be given daily in two subcutaneous divided doses with dosage titrated against the woman's booking or most recent weight."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 141,
            "data": {
                "is_heading": 1,
                "text": "Calculation of initial doses of drugs by early pregnancy weight"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 142,
            "data": {
                "is_heading": 0,
                "text": "Enoxaparin 1 mg/kg twice daily;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 143,
            "data": {
                "is_heading": 0,
                "text": "Dalteparin 100 units/kg twice daily;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 144,
            "data": {
                "is_heading": 0,
                "text": "Tinzaparin (175 units/kg) once daily."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 145,
            "data": {
                "is_heading": 1,
                "text": "LMWH Therapeutic Dose"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 146,
            "data": {
                "is_heading": 0,
                "text": "Initial dose Early pregnancy weight (kg)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 147,
            "data": {
                "is_heading": 0,
                "prefix": 50.0,
                "text": "50\u201369 70\u201389 > 90"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 148,
            "data": {
                "is_heading": 0,
                "prefix": 8000.0,
                "text": "Enoxaparin 40 mg bd  mg bd  mg bd 100 mg bd Dalteparin iu bd iu bd iu bd 10,000 iu bd"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 149,
            "data": {
                "is_heading": 0,
                "text": "Tinzaparin 175 units/kg once daily (all weights)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 150,
            "data": {
                "is_heading": 0,
                "text": "bd = twice daily"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 151,
            "data": {
                "is_heading": 1,
                "text": "Maintenance treatment of VTE"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 152,
            "data": {
                "is_heading": 0,
                "text": "Treatment with therapeutic doses of subcutaneous LMWH 12 hourly; should be employed during the remainder of the pregnancy."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 153,
            "data": {
                "is_heading": 0,
                "text": "Arrangements should be made to allow safe disposal of needles and syringes."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 154,
            "data": {
                "is_heading": 1,
                "text": "Should Blood Tests be performed to monitor LMWH therapy in pregnancy?"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 155,
            "data": {
                "is_heading": 0,
                "prefix": 50.0,
                "text": "Routine measurement of peak anti-Xa activity for patients on LMWH for treatment of acute VTE in pregnancy or postpartum is not recommended except in women at extremes of body weight (less than  kg and 90 kg or more) or with other complicating factors (for example with renal impairment or recurrent VTE) putting them at high risk."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 156,
            "data": {
                "is_heading": 0,
                "text": "In these cases, satisfactory anti-Xa levels at 3hours post injection (peak anti-Xa activity) is 0.5 1.2 units/ml."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 157,
            "data": {
                "is_heading": 0,
                "text": "Routine platelet count monitoring should not be carried out for women who receive LMWH only (unless unfractionated heparin has been given)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 158,
            "data": {
                "is_heading": 0,
                "prefix": 14.0,
                "text": "If unfractionated heparin is employed, or if the obstetric patient is receiving LMWH after first receiving unfractionated heparin, or if she has received unfractionated heparin in the past, the platelet count should ideally be monitored every other day from day 4 to day  or until heparin is stopped, whichever occurs first."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 159,
            "data": {
                "is_heading": 0,
                "text": "Any exposure to unfractionated heparin is associated with an increased risk of heparin induced thrombocytopenia."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 160,
            "data": {
                "is_heading": 1,
                "text": "Appendix B"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 161,
            "data": {
                "is_heading": 1,
                "text": "Unfractionated Heparin"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 162,
            "data": {
                "is_heading": 0,
                "text": "If massive PTE is confirmed, intravenous unfractionated heparin is the preferred treatment in massive PTE with cardiovascular compromise. In extreme circumstances prior to confirmation, immediate thrombolysis should be considered."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 163,
            "data": {
                "is_heading": 0,
                "text": "These patients need to be managed at ITU under multidisciplinary team (physician, haematologist and radiologist)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 164,
            "data": {
                "is_heading": 0,
                "text": "One of the regimens for the administration of intravenous unfractionated heparin is as follows:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 165,
            "data": {
                "is_heading": 0,
                "text": "Loading dose of 80 units/ kg, followed by a continuous intravenous infusion of 18 units/ kg/ hour."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 166,
            "data": {
                "is_heading": 0,
                "text": "If a woman has received thrombolysis (see below), the loading dose of heparin should be omitted and an infusion started at 18 units/ kg/ hour."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 167,
            "data": {
                "is_heading": 0,
                "text": "It is mandatory to measure activated partial thromboplastin time (APTT) 4\u20136 hours after the loading dose, 6 hours after any dose change and then at least daily when in the therapeutic range."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 168,
            "data": {
                "is_heading": 0,
                "text": "The therapeutic target APTT ratio is usually 1.5\u20132.5 times the average laboratory control value."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 169,
            "data": {
                "is_heading": 0,
                "text": "Using this weight-adjusted regimen, the infusion rate should be adjusted according to the APTT as shown in the table below:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 170,
            "data": {
                "is_heading": 1,
                "text": "Infusion rates according to activated partial thromboplastin time (APTT)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 171,
            "data": {
                "is_heading": 1,
                "text": "APTT ratio   Dose change    Additional action   Next APTT (hours) (units/kg/hour)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 172,
            "data": {
                "is_heading": 0,
                "prefix": 6.0,
                "text": "+ 4   Re-bolus  units/kg   6 1.2\u20131.5   + 2   Re-bolus  units/kg    6 1.5\u20132.5   No change   24 2.5\u20133.0   \u2013 2"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 173,
            "data": {
                "is_heading": 0,
                "prefix": 6.0,
                "text": ">    \u2013 3   Stop infusion 1 hour"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 174,
            "data": {
                "is_heading": 0,
                "text": "There is technically problematic in APTT monitoring of unfractionated heparin, particularly in late pregnancy when an apparent heparin resistance occurs because of increased fibrinogen and factor VIII, which influence the APTT. This can lead to unnecessarily high doses of heparin being used, with subsequent haemorrhagic problems."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 175,
            "data": {
                "is_heading": 0,
                "text": "Where such problems are considered to exist, senior haematologists should be involved in the patient's management."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 176,
            "data": {
                "is_heading": 1,
                "text": "It may be useful to determine the anti-Xa level as a measure of heparin dose. With unfractionated heparin, a lower level of anti-Xa is considered therapeutic (target range 0.35\u2013 0.70 units/ml or 0.5\u20131.0 units/ml for women with life-threatening PTE)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 177,
            "data": {
                "is_heading": 0,
                "prefix": 14.0,
                "text": "The platelet count should ideally be monitored every other day from day 4 to day  or until heparin is stopped, whichever occurs first."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 178,
            "data": {
                "is_heading": 1,
                "text": "Pregnant women who develop heparin-induced thrombocytopenia or have heparin allergy and require continuing anticoagulant therapy should be managed with the heparinoid, danaparoid sodium or fondaparinux, under specialist advice."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 179,
            "data": {
                "is_heading": 0,
                "text": "Prolonged unfractionated heparin use during pregnancy may result in osteoporosis and fractures."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 180,
            "data": {
                "is_heading": 1,
                "text": "Appendix C"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 181,
            "data": {
                "is_heading": 1,
                "text": "Warfarin"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 182,
            "data": {
                "is_heading": 0,
                "text": "Warfarin should be avoided until at least the third day and for longer in women at increased risk of postpartum haemorrhage."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 183,
            "data": {
                "is_heading": 0,
                "text": "Daily testing of the international normalised ratio (INR) is recommended during the transfer from LMWH to warfarin to avoid over anticoagulation."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 184,
            "data": {
                "is_heading": 0,
                "text": "The INR should be checked on day 2 of warfarin treatment and subsequent warfarin doses titrated to maintain the INR between 2 to 3."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 185,
            "data": {
                "is_heading": 0,
                "text": "Heparin treatment should be continued until the INR is greater than 2 on two successive days."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 186,
            "data": {
                "is_heading": 1,
                "text": "Suggested protocol for commencing warfarin treatment in the puerperium (adapted from British Society for Haematology Guidelines, 1998)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 187,
            "data": {
                "is_heading": 1,
                "text": "Day of treatment   INR   Dose (mg)"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 188,
            "data": {
                "is_heading": 0,
                "prefix": 5.0,
                "text": "First   7.0 Second  7.0 Third    7.0 2.0\u20132.1"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 189,
            "data": {
                "is_heading": 0,
                "prefix": 2.0,
                "text": "2.2\u20132.3  4.5 2.4\u20132.5  4.0 2.6\u20132.7  3.5 2.8\u20132.9  3.0 3.0\u20133.1  2.5 3.2\u20133.3"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 190,
            "data": {
                "is_heading": 0,
                "prefix": 1.5,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 191,
            "data": {
                "is_heading": 0,
                "prefix": 0.5,
                "text": "1.0 3.6\u20134.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 192,
            "data": {
                "is_heading": 0,
                "prefix": 0.0,
                "text": ">"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 193,
            "data": {
                "is_heading": 0,
                "text": "Fourth    > 8.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 194,
            "data": {
                "is_heading": 0,
                "prefix": 8.0,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 195,
            "data": {
                "is_heading": 0,
                "prefix": 7.5,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 196,
            "data": {
                "is_heading": 0,
                "prefix": 7.0,
                "text": "1.6\u20131.7"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 197,
            "data": {
                "is_heading": 0,
                "prefix": 6.5,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 198,
            "data": {
                "is_heading": 0,
                "prefix": 6.0,
                "text": ""
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 199,
            "data": {
                "is_heading": 0,
                "prefix": 5.5,
                "text": "2.0\u20132.1"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 200,
            "data": {
                "is_heading": 0,
                "prefix": 5.0,
                "text": "2.2\u20132.3"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 201,
            "data": {
                "is_heading": 0,
                "prefix": 4.5,
                "text": "2.4\u20132.6"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 202,
            "data": {
                "is_heading": 0,
                "prefix": 4.0,
                "text": "2.7\u20133.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 203,
            "data": {
                "is_heading": 0,
                "prefix": 3.5,
                "text": "3.1\u20133.5"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 204,
            "data": {
                "is_heading": 0,
                "prefix": 3.0,
                "text": "3.6\u20134.0"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 205,
            "data": {
                "is_heading": 0,
                "text": "4.1\u20134.5  Omit next day's dose then give 2 mg"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 206,
            "data": {
                "is_heading": 0,
                "prefix": 4.5,
                "text": ">   Omit two day's doses then give 1 mg"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 207,
            "data": {
                "is_heading": 0,
                "text": "INR = international normalised ratio"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 208,
            "data": {
                "is_heading": 1,
                "text": "Appendix D"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 209,
            "data": {
                "is_heading": 1,
                "text": "Information for Consent"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 210,
            "data": {
                "is_heading": 0,
                "text": "CXR - The radiation dose to the fetus from a chest X-ray performed at any stage of pregnancy is negligible."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 211,
            "data": {
                "is_heading": 1,
                "text": "Perfusion (V/Q) scanning - It is radionuclide imaging:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 212,
            "data": {
                "is_heading": 0,
                "text": "V/Q scanning may be used as a first-line investigation in pregnancy because of its high negative predictive value in this situation and its substantially lower radiation dose to pregnant breast tissue;"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 213,
            "data": {
                "is_heading": 1,
                "text": "V/Q scanning carries a slightly increased risk of childhood cancer compared with CTPA (1/280,000 versus less than 1/1,000,000);"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 214,
            "data": {
                "is_heading": 0,
                "text": "If it is performed in post-partum period \u2013 no breast feeding for 24 hours."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 215,
            "data": {
                "is_heading": 1,
                "text": "CTPA \u2013 CTPA requires iodinated contrast medium:"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 216,
            "data": {
                "is_heading": 0,
                "text": "It carries radiation exposure at least 0.5 mSv to the fetus and 5\u201330 mSv to the mother."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 217,
            "data": {
                "is_heading": 1,
                "text": "Maternal Risk"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 218,
            "data": {
                "is_heading": 0,
                "text": "While CTPA is associated with a lower risk of radiation for the fetus, relatively high radiation dose (20 mGy) to the mother's thorax and, in particular, breast tissue."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 219,
            "data": {
                "is_heading": 1,
                "text": "The delivery of 10 mGy of radiation to a woman's breast increases her lifetime risk of developing breast cancer. It has been estimated that the increased risk is 13.6% (background risk 1/200). This is particularly relevant when it is known that only around 5% of such investigations will have a positive result."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 220,
            "data": {
                "is_heading": 0,
                "text": "Breast tissue is especially sensitive to radiation exposure during pregnancy and it therefore seems sensible to recommend that lung perfusion scans (V/Q scan) should be considered the investigation of first choice for young women, especially if there is a family history of breast cancer or the woman has had a previous chest CT scan."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 221,
            "data": {
                "is_heading": 0,
                "text": "In addition, CTPA may not identify small peripheral PTE."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 222,
            "data": {
                "is_heading": 1,
                "text": "Fetal Risks"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 223,
            "data": {
                "is_heading": 0,
                "text": "The average fetal radiation dose with CTPA is less than 10% of that with V/Q scanning during all trimesters of pregnancy."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 224,
            "data": {
                "is_heading": 0,
                "text": "There have been concerns over the safety of iodinated contrast medium with CTPA, as this can potentially alter fetal or neonatal thyroid function."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 225,
            "data": {
                "is_heading": 0,
                "text": "Now thought to be unfounded, that giving an iodine based contrast injection for CTPA may induce hypothyroidism in the baby, but no need for thyroid function of the baby after an isotope study (discussed with paediatrician and radiologist)."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 226,
            "data": {
                "is_heading": 0,
                "text": "Current European guidelines indicate that iodinated contrast media may be given to a pregnant woman when radiographic examination is essential."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 227,
            "data": {
                "is_heading": 1,
                "text": "Appendix E"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 228,
            "data": {
                "is_heading": 1,
                "text": "Other Managements"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 229,
            "data": {
                "is_heading": 0,
                "text": "Under multidisciplinary team - consultant physician, cardiothoracic surgeon, radiologist, haematologist, anaesthetist and obstetrician."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 230,
            "data": {
                "is_heading": 1,
                "text": "Thrombolytic therapy (streptokinase, urokinase and recombinant tissue plasminogen activator):"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 231,
            "data": {
                "is_heading": 0,
                "text": "Thrombolytic therapy should be reserved for women with severe pulmonary thromboembolism with haemodynamic compromise."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 232,
            "data": {
                "is_heading": 0,
                "text": "Problem associated with thrombolysis is the maternal bleeding complication rate of 1\u2013 6%."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 233,
            "data": {
                "is_heading": 1,
                "text": "Urgent Thoracotomy"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 234,
            "data": {
                "is_heading": 0,
                "text": "If the woman is not suitable for thrombolysis or is moribund, a discussion with the cardiothoracic surgeons with a view to urgent thoracotomy should be undertaken."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 235,
            "data": {
                "is_heading": 1,
                "text": "The use of a temporary inferior vena caval filter should be considered in the perinatal period for women with iliac vein VTE, to reduce the risk of PTE or in women with proven DVT and who have continuing PTE despite adequate anticoagulation."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 236,
            "data": {
                "is_heading": 0,
                "text": "In patients with severe acute venous obstruction e.g. critical limb ischaemia, thrombolytic therapy (cather-directed or systemic) or thrombectomy should be considered. Discuss such cases urgently with consultant interventional radiologist and consultant vascular surgeon."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 237,
            "data": {
                "is_heading": 1,
                "text": "Graduated elastic compression stocking"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 238,
            "data": {
                "is_heading": 0,
                "text": "In the initial management of DVT, the leg should be elevated and a graduated elastic compression stocking applied to reduce oedema. Mobilisation with graduated elastic compression stockings should be encouraged."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 239,
            "data": {
                "is_heading": 0,
                "text": "This approach can also prevent the development of post-thrombotic syndrome and does not increase the likelihood of developing PTE."
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 240,
            "data": {
                "is_heading": 1,
                "text": "Appendix F"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 241,
            "data": {
                "is_heading": 1,
                "text": "Risk Assessment for VTE Antenatal Notes"
            }
        },
        {
            "type": "image",
            "sequence_num": 242,
            "data": {
                "url": "12007 VTE DVT  PE during antenatal & postnatal period 3.1.003.jpeg"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 243,
            "data": {
                "is_heading": 1,
                "text": "Risk Assessment for VTE Labour Care Notes"
            }
        },
        {
            "type": "image",
            "sequence_num": 244,
            "data": {
                "url": "12007 VTE DVT  PE during antenatal & postnatal period 3.1.003.jpeg"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 245,
            "data": {
                "is_heading": 1,
                "text": "Risk Assessment for VTE Postnatal Maternal Notes"
            }
        },
        {
            "type": "image",
            "sequence_num": 246,
            "data": {
                "url": "12007 VTE DVT  PE during antenatal & postnatal period 3.1.004.jpeg"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 247,
            "data": {
                "is_heading": 0,
                "text": "Management of women with venous thromboembolism (VTE), deep vein thrombosis (DVT) or pulmonary embolism (PE) during antenatal and postnatal period / 12007 / 3.1"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 248,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": ""
            }
        },
        {
            "type": "image",
            "sequence_num": 249,
            "data": {
                "url": "12007 VTE DVT  PE during antenatal & postnatal period 3.1.005.jpeg"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 250,
            "data": {
                "is_heading": 1,
                "text": "Appendix G: Preliminary Equality Analysis"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 251,
            "data": {
                "is_heading": 1,
                "text": "This assessment relates to: Management of Women with Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE) During Antenatal and"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 252,
            "data": {
                "is_heading": 0,
                "text": "Postnatal Period (12007)"
            }
        },
        {
            "type": "table",
            "sequence_num": 253,
            "data": {
                "num_rows": 9,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "A change in a service to patients"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A change to an existing policy"
                    },
                    {
                        "text": "X"
                    },
                    {
                        "text": "A change to the way staff work"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "A new policy"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Something else (please give details)"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": "Questions"
                    },
                    {
                        "text": "Answers"
                    },
                    {
                        "text": "What are you proposing to change?"
                    },
                    {
                        "text": "Full Review"
                    },
                    {
                        "text": "Why are you making this change? (What will the change achieve?)"
                    },
                    {
                        "text": "3 year review"
                    },
                    {
                        "text": "Who benefits from this change and how?"
                    },
                    {
                        "text": "Patients and clinicians"
                    },
                    {
                        "text": "Is anyone likely to suffer any negative impact as a result of this change? If no, please record reasons here and sign and date this assessment. If yes, please complete a full EIA."
                    },
                    {
                        "text": "No"
                    },
                    {
                        "text": "a) Will you be undertaking any consultation as part of this change? b) If so, with whom?"
                    },
                    {
                        "text": "Refer to pages 1 and 2"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 254,
            "data": {
                "is_heading": 1,
                "text": "Preliminary analysis completed by:"
            }
        },
        {
            "type": "table",
            "sequence_num": 255,
            "data": {
                "num_rows": 1,
                "num_cols": 6,
                "table_items": [
                    {
                        "text": "Name"
                    },
                    {
                        "text": "Anita Dutta"
                    },
                    {
                        "text": "Job Title"
                    },
                    {
                        "text": "Consultant Obstetrician"
                    },
                    {
                        "text": "Date"
                    },
                    {
                        "text": "June 2019"
                    }
                ]
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 256,
            "data": {
                "is_heading": 0,
                "text": "Management of women with venous thromboembolism (VTE), deep vein thrombosis (DVT) or pulmonary embolism (PE) during antenatal and postnatal period / 12007 / 3.1"
            }
        },
        {
            "type": "ListItem",
            "sequence_num": 257,
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": ""
            }
        }
    ]
}